Biodesix, Inc., a leading player in the precision medicine industry, is headquartered in the United States. Founded in 2010, the company has made significant strides in the development of innovative diagnostic solutions, particularly in the field of lung cancer. Biodesix focuses on utilising advanced genomic and proteomic technologies to provide actionable insights for oncologists, enhancing patient care through personalised treatment options. The company’s core offerings include its proprietary blood-based tests, which are designed to identify specific biomarkers associated with lung cancer. This unique approach not only aids in early detection but also helps in tailoring therapies to individual patient profiles. Biodesix has established a strong market position, recognised for its commitment to improving patient outcomes and advancing the field of oncology diagnostics.
How does Biodesix, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Biodesix, Inc.'s score of 32 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biodesix, Inc., headquartered in the United States, currently does not report any specific carbon emissions data. However, the company is committed to addressing climate change through various initiatives. Biodesix has signed the Climate Pledge, affirming its dedication to achieving net-zero carbon emissions. This commitment was formalised on 21 March 2022. In terms of reduction targets, Biodesix is classified as "Committed" under the Science Based Targets initiative (SBTi), indicating that it is actively working towards establishing specific emissions reduction goals. While no absolute emissions figures are available, the company is part of the healthcare providers and services sector, which is increasingly focusing on sustainability and reducing its carbon footprint. As of now, Biodesix has not disclosed specific near-term or long-term reduction targets, but its commitment to the Climate Pledge and SBTi demonstrates a proactive approach to climate action. The company is expected to develop and announce more detailed strategies in the future to align with industry standards and expectations.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biodesix, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
